A CONSTITUTIVELY ACTIVE MUTANT THYROTROPIN-RELEASING-HORMONE RECEPTORIS CHRONICALLY DOWN-REGULATED IN PITUITARY-CELLS - EVIDENCE USING CHLORDIAZEPOXIDE AS A NEGATIVE ANTAGONIST
M. Heinflink et al., A CONSTITUTIVELY ACTIVE MUTANT THYROTROPIN-RELEASING-HORMONE RECEPTORIS CHRONICALLY DOWN-REGULATED IN PITUITARY-CELLS - EVIDENCE USING CHLORDIAZEPOXIDE AS A NEGATIVE ANTAGONIST, Molecular endocrinology, 9(11), 1995, pp. 1455-1460
A carboxyl-terminus truncated mutant of the guanine nucleotide-binding
(G) protein-coupled TRH receptor (TRH-R) was previously shown to exhi
bit constitutive, Le. TRH-independent, activity (C335Stop TRH-R). Chlo
rdiazepoxide (CDE), a known competitive inhibitor of TRH binding to wi
ld-type (WT) TRH-Rs, is shown to compete for binding to C335Stop TRH-R
s also. More importantly, CDE is shown to be a negative antagonist of
C335Stop TRH-Rs. CDE rapidly caused the basal rate of inositol phospha
te second messenger (IP) formation to decrease in AtT-20 pituitary cel
ls stably expressing C335Stop TRH-Rs (AtT-C335Stop cells), but not in
cells expressing WT TRH-Rs (AtT-WT cells). Similar observations were m
ade in HeLa cells transiently expressing C335Stop or WT TRH-Rs. CDE in
hibition of IP formation was shown to be specific for TRH-Rs using GH(
4)C(1) cells expressing both TRH-Rs and receptors for bombesin, in the
se cells, CDE inhibited TRH-stimulated IP formation, but had no effect
on bombesin-stimulated IP formation. The effects of chronic administr
ation of CDE were studied. Preincubation of AtT-C335Stop cells, but no
t AtT-WT cells, with CDE for several hours caused an increase in cell
surface receptor number (up-regulation) that led to increased TRH stim
ulation of inositol phosphate formation and elevation of intracellular
free Ca2+. Preincubation with CDE did not affect methyl-TRH binding a
ffinity or TRH potency in cells expressing AtT-C335Stop or in AtT-WT c
ells. We conclude that CDE is a negative antagonist of C335Stop TRH-Rs
and that constitutively active C335Stop TRH-Rs are down-regulated in
AtT-20 pituitary cells in the absence of agonist.